Validation of a multiplex immunoassay for serum angiogenic factors as biomarkers for aggressive prostate cancer.
about
Recommendations for Use and Fit-for-Purpose Validation of Biomarker Multiplex Ligand Binding Assays in Drug Development.A Multiplex Microsphere-Based Immunoassay Increases the Sensitivity of SIV-Specific Antibody Detection in Serum Samples and Mucosal Specimens Collected from Rhesus Macaques Infected with SIVmac239Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer.Biomarkers of reactive resistance and early disease progression during chemotherapy plus bevacizumab treatment for colorectal carcinoma.Integrated analyses of proteins and their glycans in a magnetic bead-based multiplex assay format.Validation of a multiplex electrochemiluminescent immunoassay platform in human and mouse samples.A novel multiplexed immunoassay identifies CEA, IL-8 and prolactin as prospective markers for Dukes' stages A-D colorectal cancers.Effects of definitive chemoradiation on circulating immunologic angiogenic cytokines in head and neck cancer patients.Analysis of serum protein glycosylation by a differential lectin immunosorbant assay (dLISA).Diagnostic Value of Serum Angiogenesis Markers in Ovarian Cancer Using Multiplex ImmunoassayFollistatin as potential therapeutic target in prostate cancer.Systems for multiplexing homogeneous immunoassays.Translating pharmacodynamic biomarkers from bench to bedside: analytical validation and fit-for-purpose studies to qualify multiplex immunofluorescent assays for use on clinical core biopsy specimens.A microfluidic multiplex proteomic immunoassay device for translational researchEffects of some natural immunomodulatory compounds in combination with thalidomide on survival rate and tumor size in fibrosarcoma-bearing mice.Development of a reliable assay to measure glypican-1 in plasma and serum reveals circulating glypican-1 as a novel prostate cancer biomarker.A pilot study to profile salivary angiogenic factors to detect head and neck cancers.
P2860
Q28081875-D28DEF0B-417D-4227-8E47-C0E7ED18A876Q28383579-F0F526DC-D2AA-4B63-BD48-0606E068FC13Q33413742-2847C6EE-071D-46A7-B1C9-4B166626651BQ33757046-08114AF2-B7D3-418D-929C-DC6D94A829EBQ33977544-B999F4D5-99ED-4CAB-A336-63313641C4BDQ33997620-C0D1EF10-EB63-48D4-8F34-385B851FFFA7Q35619009-CA56A140-AAD4-4261-96FE-0CB8756036A1Q37024656-02DD26B3-AFD1-48FB-B8B4-8F5CBEC97D11Q37357377-06807CCB-CB11-4969-B917-9C3D1339908BQ37631567-A21E1964-42B2-4854-B8D8-E6A980C4584EQ38086102-77734A08-7B99-4D27-B13A-F2582D6330FCQ38546020-A2BC6EF2-BEB5-4CE5-8E1E-EAA8813FF7A1Q38963126-25EE2D3D-AD1F-4B1D-93AA-C09503A06DC2Q41842918-095B015D-802F-4E69-94EB-B826763ADDC5Q42258029-99E9AA11-033A-48EC-AA92-337EFE999283Q54996010-14F53E54-5D63-4A83-BFC2-BADEC1D2E956Q55717838-D2C79007-E1ED-40AB-96E7-8E1B4499CCA6
P2860
Validation of a multiplex immunoassay for serum angiogenic factors as biomarkers for aggressive prostate cancer.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Validation of a multiplex immu ...... or aggressive prostate cancer.
@en
Validation of a multiplex immu ...... or aggressive prostate cancer.
@nl
type
label
Validation of a multiplex immu ...... or aggressive prostate cancer.
@en
Validation of a multiplex immu ...... or aggressive prostate cancer.
@nl
prefLabel
Validation of a multiplex immu ...... or aggressive prostate cancer.
@en
Validation of a multiplex immu ...... or aggressive prostate cancer.
@nl
P2093
P2860
P1433
P1476
Validation of a multiplex immu ...... or aggressive prostate cancer.
@en
P2093
Daniel W Chan
Hanching Chiu
Vinita Gupta
P2860
P304
P356
10.1016/J.CCA.2012.06.017
P577
2012-06-18T00:00:00Z